Compare Abeona Therapeutics Inc (ABEO) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs KB Financial Group, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while KB Financial Group, Inc. trades at $116.82 (market cap $39.97B). The key difference: KB Financial Group, Inc. is far larger — about 107.1× Abeona Therapeutics Inc's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KB | |
|---|---|---|
Market Cap | $373.32M | $39.97B |
Sector | Health | Financials |
52-Week High | $7.23 | $118.21 |
52-Week Low | $4.17 | $77.50 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
KB trades at $115.48, up 5.61% today, showing strong momentum near its 52-week high. Recent quarters have consistently beaten earnings expectations, with Q1 2026 EPS of $3.49 surpassing estimates. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust revenue growth to $21.23T in 2025 and a healthy net income margin of 27.82%.
Outlook remains positive given earnings beats and valuation appeal with a P/E of 10.95, though risks include volatile cash flows and high interest expenses. Analyst sentiment is mixed with 33% buy ratings, suggesting cautious optimism for continued performance if execution aligns with growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
